KRT17 and cancer: These preclinical results thus provided a strong support for the in vitro evidence, depicting a novel miRNA-485-5p/KRT17/integrin/FAK/Src/ERK/β-catenin signaling axis that can be exploited for future drug design for cancer stem cell suppression, as well as drug sensitization in OSCC (Fig. 7E).